Eduardo Castañón Álvarez

Eduardo Castañón Álvarez

Auto-generated profile, based on publicly available information

Eduardo Castañón Álvarez

Clinica Universidad de Navarra 4 Department of Oncology Pamplona, Spain

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2025 in Journal of Clinical Oncology
Verified
Journal Article
Open access
IMIvan Marquez-Rodas
Ivan Marquez-Rodas
CDCaroline Dutriaux
Caroline Dutriaux
PSPhilippe Saiag
Philippe Saiag
LCLuis De la Cruz-Merino
Luis De la Cruz-Merino
EÁEduardo Castañón Álvarez
Eduardo Castañón Álvarez
SDStephane Dalle
Stephane Dalle
PURPOSE: Patients with anti–PD-1–resistant melanoma (MEL) have no well-defined standard of care. BO-112 is a synthetic, double-stranded RNA (poly I:C) nanoplexed with polyethylenimine that when administered intratumorally has showed in patients with solid tumors potential to revert this resistance. We report efficacy and safety of the phase II clinical trial of intratumoral BO-112 plus intravenous pembrolizumab for patients with anti–PD-1–resistant MEL (ClinicalTrials.gov identifier: NCT04570332 ). METHODS: Forty-two patients were treated with intratumoral BO-112 once every week for 7 weeks and then once every 3 weeks (up to 2 mg and up to eight lesions per treatment) combined with 200 mg pembrolizumab once every 3 weeks until progressive disease, unacceptable toxicity, death, or up to 1 year. Primary end point was RECIST 1.1 objective response rate (ORR) by independent central radiology review in modified intention-to-treat population (mITT; patients evaluable for response) with 20% ORR positivity threshold. Secondary key end points were progression-free survival (PFS), overall survival (OS), duration of response (DOR), and safety. RESULTS: For mITT, there were 40 patients and the ORR was 25%, with 10% complete, 15% partial, and 40% stable disease, with nonachieved (NA) median DOR (95% CI, 8.3 to NA). For ITT, there were 42 patients, and the median PFS and OS were 3.7 months (95% CI, 2.2 to 9.2) and NA (95% CI, 9.9 to NA), respectively, with 54% patients alive at 24 months. The combination was well tolerated: 16 patients (38.1%) experiencing ≥G3-4 adverse events, four (9.5%) drug-related, and no deaths related to treatment. CONCLUSION: The clinical trial has met its primary end point (ORR) making BO-112 with pembrolizumab a potential strategy to revert anti–PD-1 resistance in patients with MEL. PFS results are in line with other clinical trials in anti–PD-1–resistant scenario, with promising OS data.

12 February 2025 in Clinical Cancer Research
Verified
Journal Article
Open access
LSLillian L. Siu
Lillian L. Siu
SPSophie Postel-Vinay
Sophie Postel-Vinay
RVRafael Villanueva-Vázquez
Rafael Villanueva-Vázquez
Guillermo De VelascoGuillermo De Velasco
Guillermo De Velasco
EAEduardo Castanon Alvarez
Eduardo Castanon Alvarez
CMChristophe Massard
Christophe Massard
Purpose: AZD8701 uses next-generation antisense oligonucleotide (ASO) technology to selectively reduce human forkhead box P3 (FOXP3) expression in regulatory T cells, reversing their immunosuppressive function. FOXP3 ASO alone or with PD-(L)1 inhibition attenuated tumor growth in mice. We report a phase I study of AZD8701 alone or combined with durvalumab in patients with advanced solid tumors. Patients and Methods: Eligible patients had solid tumors and received prior standard-of-care treatment, including anti–PD-(L)1 therapy. Patient cohorts were treated with AZD8701 intravenously weekly at escalating doses, either alone (60–960 mg) or combined (240–720 mg) with durvalumab 1,500 mg intravenous every 4 weeks. The primary objective was safety and tolerability, with the aim of determining the MTD. Results: Forty-five patients received AZD8701 monotherapy, and 18 received AZD8701 with durvalumab. One dose-limiting toxicity (increased alanine aminotransferase) occurred with AZD8701 960 mg. The most common adverse events related to AZD8701 monotherapy were fatigue (22.2%), asthenia, pyrexia, and increased alanine aminotransferase (20% each); the safety profile was similar when combined with durvalumab. With AZD8701 monotherapy, 24.4% and 15.6% of the patients had stable disease for ≥16 and ≥24 weeks, respectively; one patient treated with AZD8701 720 mg and durvalumab had a partial response. FOXP3 mRNA changes were heterogeneous (8/13 patients showed a reduction), with no clear dose relationship. ASO accumulated in the tumor epithelium and stroma. Conclusions: This study demonstrates the clinical feasibility of ASO therapy, with generally manageable adverse events, FOXP3 knockdown, and ASO delivery to the tumor.

3 September 2025 in Cancer Research Communications
Verified
Journal Article
Open access
JPJohn Powderly
John Powderly
MIMartina Imbimbo
Martina Imbimbo
ANTOINE ITALIANOANTOINE ITALIANO
ANTOINE ITALIANO
PMPatricia Martin-Romano
Patricia Martin-Romano
MMMeredith McKean
Meredith McKean
AHAntoine Hollebecque
Antoine Hollebecque
Purpose: Blocking enzymatic activity of cluster of differentiation 39 (CD39) with IPH5201 may promote antitumor immunity by increasing immunostimulatory adenosine triphosphate and reducing immunosuppressive adenosine levels in the tumor microenvironment. This first-in-human, phase 1 study evaluated IPH5201 as monotherapy or in combination with durvalumab (anti-PD-L1) in patients with advanced solid tumors. Patients and Methods: The study consisted of two consecutive dose-escalation parts: IPH5201 monotherapy (100, 300, 1000 and 3000 mg) every 3 weeks (Q3W) and IPH5201 (300, 1000 and 3000 mg) + durvalumab 1500 mg Q3W. The primary endpoint was to evaluate safety and tolerability. Secondary endpoints included antitumor activity, pharmacokinetics and immunogenicity. Results: Overall, 38 patients received IPH5201 monotherapy and 19 received IPH5201 + durvalumab, with median duration of follow-up 7.6 months (range, 1.0–23.7). The most common cancer types were pancreatic (42.1%), non-small-cell lung (19.3%), and colorectal (17.5%). The most common treatment-related adverse events (AEs) were infusion-related reactions and fatigue. There were no AE-related deaths and the maximum tolerated dose was not reached. Overall, 23/57 patients (40.4%) had stable disease as their best overall response. IPH5201 exhibited linear PK profile and estimated terminal half-life of 8 to 9 days at higher doses. On-treatment tumor biopsies revealed decreased CD39 ATPase activity in 5/7 patients, including all evaluable patients receiving the maximum dose of IPH5201 3000 mg Q3W. Conclusions: IPH5201 as monotherapy, or in combination with durvalumab, was well tolerated at pharmacologically active doses that induced reduction of intratumoral CD39 enzymatic activity and showed preliminary evidence for disease stabilization.

10 May 2026 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
MVMaría Vieito
María Vieito
EFElisa Fontana
Elisa Fontana
CHCatherine Hye-won Han
Catherine Hye-won Han
ECEduardo Castanon
Eduardo Castanon
David James PinatoDavid James Pinato
David James Pinato
NKNino Keshelava
Nino Keshelava
PURPOSE: BRAF V600 mutations are tumor-agnostic oncogenic drivers whose targeted inhibition is challenged by therapeutic resistance. Mosperafenib is a novel paradox breaker and brain-penetrant BRAF inhibitor (BRAFi), tested in this study for safety, maximum tolerated dose (MTD), pharmacokinetics (PK), and preliminary clinical activity. PATIENTS AND METHODS: This phase Ia/b study was conducted in patients with advanced solid tumors harboring a BRAF V600 mutation (ISRCTN13713551). The modified continuous reassessment method guided dose escalation of mosperafenib, which was given orally up to 3,600 mg once daily in 28-day cycles. The primary objective was to estimate the MTD and/or recommended phase II dose(s). RESULTS: Eighty patients (60% BRAFi-exposed)—63 with colorectal cancer (CRC), 13 with melanoma, and 4 with other solid tumors—received ≥1 dose of mosperafenib as a single agent for a median of 3.7 months (range, 0.2-28.6). Two dose-limiting grade 3 toxicities of rash and rash maculopapular were reported. MTD was not reached. Grade 3 to 4 treatment-related adverse events (TRAEs) occurred in 13 patients (16.3%); no grade 5 TRAEs events were reported. Two patients (2.5%) discontinued study treatment due to TRAEs. There were no reports of palmar-plantar erythrodysesthesia or keratoacanthoma. Linear and time-independent PK was demonstrated across the tested dose range, achieving exposure levels with sustained PK-derived pERK inhibition ≥90%. An exposure-response relationship was observed. Overall response rate was 24.2%, including two complete responses and 14 partial responses. Median progression-free survival was 6.4 months in patients with CRC (200 mg once daily-1200 mg three times a day) and 3.5 months in patients with melanoma (200 mg once daily-800 mg twice a day). CONCLUSION: Mosperafenib demonstrated a favorable safety profile, sustained target inhibition, and early signs of clinically meaningful single-agent activity in BRAFi-naïve and BRAFi-exposed patients.

18 March 2026 in Clinical Cancer Research
Verified
Journal Article
Open access
BTBen Tran
Ben Tran
MVMark Voskoboynik
Mark Voskoboynik
SKSang-We Kim
Sang-We Kim
CLCharlotte Lemech
Charlotte Lemech
ECEnric Carcereny
Enric Carcereny
SISeock-Ah Im
Seock-Ah Im
Purpose: Volrustomig is an IgG1 monovalent bispecific antibody engineered to preferentially target cytotoxic T lymphocyte–associated antigen-4 (CTLA-4) on programmed cell death protein 1 (PD-1)–positive T cells while providing adequate and durable PD-1 inhibition. The aim of this phase I, first-in-human study (NCT03530397) is to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, pharmacodynamics, and antitumor activity of volrustomig. This article reports findings for the dose-exploration and immunotherapy-naïve expansion cohorts. Patients and Methods: Patients aged ≥18 years who had histologically or cytologically confirmed advanced cancer, measurable disease, a performance status of 0 or 1, and adequate organ and marrow function received volrustomig 2.25 to 2,500 mg intravenously every 3 weeks until confirmed disease progression, initiation of alternative cancer therapy, unacceptable toxicity, or consent withdrawal. The primary objective in the dose-exploration phase was to evaluate safety and tolerability, describe dose-limiting toxicities, and determine the maximum tolerated dose. Secondary objectives included the assessment of preliminary antitumor activity and volrustomig pharmacokinetics. Results: Eighty-six patients received volrustomig treatment in the dose-exploration and immunotherapy-naïve expansion cohorts; 78 (90.7%) patients were immunotherapy-naïve. Common treatment-related adverse events (TRAE) were pruritus (30.2%), hypothyroidism (26.7%), hyperthyroidism (24.4%), and rash (24.4%). TRAEs led to treatment discontinuation in 33.7% of patients and one death. At doses ≥500 mg, volrustomig demonstrated robust peripheral and intratumoral T-cell activation and proliferation at levels greater than those seen with approved PD-1/CTLA-4 regimens. Seventeen (19.8%) patients had objective responses, including 2 (2.3%) complete responses; the median response duration was 17.5 months. Conclusions: These results support further development of volrustomig as monotherapy and in combination regimens, with phase III trials ongoing.

18 August 2026 in Clinical Cancer Research
Verified
Journal Article
Open access
Benedito A CarneiroBenedito A Carneiro
Benedito A Carneiro
TMthomas marron
thomas marron
DZDmitriy Zamarin
Dmitriy Zamarin
ECEduardo Castañón
Eduardo Castañón
SPSandip Pravin Patel
Sandip Pravin Patel
OHOmid Hamid
Omid Hamid
Purpose: MEDI1191 is a lipid nanoparticle–formulated messenger RNA (mRNA) designed to induce local interleukin (IL) 12 production and intensify antitumor T-cell responses. We report dose-escalation results from a first-in-human, open-label, phase I study of intratumoral MEDI1191 plus intravenous durvalumab (NCT03946800). Patients and Methods: Patients were ≥18 years with advanced/metastatic solid tumors and had progressed on ≥1 line of prior therapy (immunotherapy permitted). Cutaneous/subcutaneous (parts 1A and 1B) or deep-seated lesions (part 1D) were injected; patients had ≥1 noninjected lesion measurable per Response Evaluation Criteria in Solid Tumors (RECIST v1.1). Target lesions were noninjected. MEDI1191 and durvalumab were given sequentially (part 1A) or concurrently (parts 1B and 1D). Primary objectives were safety and determination of maximum tolerated dose (MTD). Secondary objectives included efficacy. Results: As of February 27, 2023, 61 patients were treated. Patients had a median of four prior regimens (range, 1–17); 39 (63.9%) received prior anti–programmed cell death protein 1/programmed cell death ligand 1 [PD-(L)1] immunotherapy. Treatment-emergent adverse events (TEAE) occurred in 96.7% of patients, and 41.0% experienced grade 3/4 TEAEs. There were no dose-limiting toxicities. The MTD was not reached. The objective response rate was 9.8%, including 1 confirmed complete response and 5 confirmed partial responses (PR). The duration of response was 2.7 to 22.3 months; the median was not reached. Responses occurred in injected lesions, local noninjected lesions, and distant lesions. Three of the 39 patients with prior anti–PD-(L)1 therapy had PRs. Conclusions: MEDI1191 and durvalumab were tolerated. Preliminary antitumor activity was encouraging in these heavily pretreated patients, including patients previously treated with immune checkpoint inhibitors.